hVIVO PLC GBP6.8m RSV human challenge contract signed (9321O)
06 Februar 2023 - 8:00AM
UK Regulatory
TIDMHVO
RNS Number : 9321O
hVIVO PLC
06 February 2023
hVIVO plc
("hVIVO" or the "Company")
GBP6.8m RSV human challenge contract signed
Second contract with an APAC client in 2023
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc)
a rapidly growing specialist contract research organisation (CRO)
and world leader in testing infectious and respiratory disease
products using human challenge clinical trials, announces that it
has signed a GBP6.8m contract with a leading pharmaceutical company
based in Asia Pacific ("APAC"), to test its respiratory syncytial
virus ("RSV") antiviral drug candidate, using the hVIVO RSV Human
Challenge Study Model.
The Phase 2a double-blinded placebo-controlled human challenge
trial will take place at the Company's specialist quarantine
facilities in Whitechapel and will evaluate the efficacy profile of
the antiviral against RSV infection in healthy volunteers. The
study is expected to commence in H1 2024, with revenue mostly
recognised in 2024. As part of the study, hVIVO will recruit
healthy volunteers via the Company's dedicated volunteer
recruitment arm, FluCamp .
RSV is the main cause of childhood lower respiratory infections
and is responsible for a significant burden of disease in the
elderly and in adults with chronic medical problems, such as COPD.
Globally it affects an estimated 50 million people annually,
leading to four million hospitalisations and approximately 60,000
in-hospital deaths in children younger than five years.(1) hVIVO
has inoculated over 1,600 healthy volunteers across 28 RSV
challenge trials to date and the challenge trial data has already
expedited the development of several RSV vaccines for a number of
pharmaceutical companies.
This is the second human challenge trial contract that hVIVO has
signed with an Asia-Pacific client in 2023 following the
identification of this region as a key growth area for the Company.
The strength of data generated from hVIVO's human challenge trials
is resulting in a growing demand from global biopharmaceutical
companies, as they seek to de-risk their development programmes
ahead of later stage field studies.
Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "We are
delighted to be working with this client on their important RSV
programme. RSV has been a particular blight on humanity with no
effective vaccine against this virus in over 60 years of R&D.
Our RSV challenge trial model is a tried and tested model that has
been used to expedite the development of several RSV vaccine
candidates, and we expect that at least one of the vaccines we have
worked on will reach patients this year. This new client will
benefit from our experience and expertise to impact their drug
development plans.
"For hVIVO, it is highly encouraging to see our global client
list continue to grow and our orderbook further diversify with our
second significant contract with an APAC client. One of our goals
for 2023 is to attract more customers from the APAC region, and we
have already seen this come to fruition with two contracts. It is a
great start to the year and builds our pipeline for 2024. We expect
to continue this strong momentum in the APAC region, and the rest
of the world, as the growing number of biopharma companies
recognise the strong value of human challenge models."
(1) Shi, T. et al. Global, regional, and national disease burden
estimates of acute lower respiratory infections due to respiratory
syncytial virus in young children in 2015: a systematic review and
modelling study. The Lancet 390, 946-958 (2017).
For further information please contact:
hVIVO plc +44 (0) 20 7756 1300
Yamin 'Mo' Khan, Chief Executive
Officer
Stephen Pinkerton, Chief Financial
Officer
Liberum Capital (Nominated Adviser and
Joint Broker) +44 (0) 20 3100 2000
Ben Cryer, Edward Mansfield, Phil Walker,
Will King
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash, Charlie Beeson, Nigel Birks,
Harriet Ward (ECM)
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR) +44 (0) 20 7933 8780 or hvivo@walbrookpr.com
Stephanie Cuthbert / Phillip +44 (0) 7796 794 663 / +44 (0) 7867 984
Marriage / 082 /
Louis Ashe-Jepson +44 (0) 7747 515 393
Notes to Editors
About hVIVO
hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly
growing specialist contract research organisation (CRO) and the
world leader in testing infectious and respiratory disease vaccines
and therapeutics using human challenge clinical trials. The Group
provides end-to-end early clinical development services to its
large, established and growing repeat client base, which includes
four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique
portfolio of 10+ human challenge models to test a broad range of
infectious and respiratory disease products, world class challenge
agent manufacturing, specialist drug development and clinical
consultancy services via its Venn Life Sciences brand, and a lab
offering via its hLAB brand, which includes virology, immunology
biomarker and molecular testing. The Group offers additional
clinical field trial services such as patient recruitment and
clinical trial site services.
hVIVO runs challenge studies in London from its Whitechapel
quarantine clinic, its state-of-the-art QMB clinic with its highly
specialised on-site virology and immunology laboratory, and its
clinic in Plumbers Row. To recruit volunteers / patients for its
studies, the Company leverages its unique clinical trial
recruitment capacity via its FluCamp volunteer screening facilities
in London and Manchester.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTUOABROWUURAR
(END) Dow Jones Newswires
February 06, 2023 02:00 ET (07:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024